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The EMBO Journal REFEREE REPORTS Referee #1 (Remarks to the Author):
This paper reports a detailed analysis of cell surface LFA-1 affinity in response to a variety of physiological and artificial stimuli. The extensive careful analysis of LFA-1 affinity provides insights into the steps involved in LFA-1 activation and is likely to be of significant interest to the integrin field. The experimental results are compelling and although the text is at times very dense the underlying logic is clearly articulated. I have only relatively minor concerns:
1) The affinity of LFA-1 (F265S/F292A) expressed in K562 cells was assessed in direct-binding assays rather than the indirect competitive radioligand binding assay used in all the other experiments -does a direct binding assay with wild-type integrin generate affinities comparable with those calculated from the indirect assay?
2) Does the high-affinity F265S/F292A mutant support adhesion?
3) Additional discussion of why MEM148 is unable to produce a high-affinity state is required. MEM148 is described as binding to a β2 hybrid domain activation epitope and inducing hybrid domain swing-out. Hence, its inability to generate high affinity LFA-1 does not appear to be consistent with the proposed activation pathway whether priming is correlated with alterations in the integrin leg conformations that then lead to hybrid domain swing out, opening of the β I-domain and ultimately activation of the α subunit I-domain. 4) At several points the authors state that results demonstrate that cell adhesion requires post-ligand binding events that open the LFA-1 headpiece and induce high affinity. What is the evidence that it is post-ligand binding? This is certainly credible, and it would be consistent with the traction model, but the proof that it is post ligand binding needs to be more clearly explained.
5) The reported results are consistent with the traction force model for activation but do not directly reveal any role for traction. This should be clear in the discussion.
Referee #2 (Remarks to the Author):
This study from Schürpf and Springer addresses an important, unresolved topic, which is the regulation of the affinity of the LFA-1/αLβ2 integrin on the surface of T cells. The authors use a high affinity mutant of ICAM-1; integrin mutants; T cell stimuli that modulate cell adhesion, e.g. chemokines and TCR/CD3 activation; conformation-sensitive and conformation-changing Fab antibody fragments; and small molecule inhibitors to study the conformational changes in LFA-1 that lead to intermediate and high affinity conformations, and how these support T cell adhesion. The major conclusions are: 1) Inside-out stimulation of LFA-1-mediated T cell adhesion produces only modest increase to the affinity of LFA-1; 2) The opening of the integrin headpiece is necessary for the acquisition of a high affinity conformation and T cell adhesion; 3) Immobilized, but not soluble ligand triggers a cellular energy-dependent conformational change.
This represents a comprehensive, well conducted study that sheds light into important questions. LFA-1 is arguably the best characterized integrin receptor in terms of its conformational changes during activation. In this work, the authors have opted for a classical biochemical approach to define the conformational changes that underlie adhesion to ICAM-1 mediated by LFA-1.
The first two major conclusions of the study are well substantiated and only minor additions and clarifications are required:
1) The authors use a galore of different reagents, which makes the study hard to follow for the nonspecialist. This could be improved by adding an additional panel to Figure 1 (G). This panel should display the binding sites and effects of the antibodies and reagents used throughout the study.
2) The difference between T lymphocytes and transfected K562 is interesting, and points to an endogenous partial activator missing in the K562 cells. The authors should study the binding of LFA-1 to Hi3-ICAM-1 in an additional, non-lymphoid cell line, to be added to panels 1C and 1D. This would reveal whether the K562 are a special case, or that T cells contain a cellular activator that triggers partial activation of LFA-1. 3) A point that needs to be solved is that in Fig. 3D , the percentage of adherent cells induced by Mn2+ seems to be rather low (only about 25%), specially taking into account the unusually high concentration of this cation employed to induce activation of LFA-1 (1 uM). Also, why are the % adherent cells so different under the "control" (basal) conditions in panels A, B, C, and D of The last conclusion of the study is less convincing. 2-DG and azide are bound to cause sledgehammer effects on the cells and are not very informative of the mechanistic effects at work here. Panels 1E and 1F suggest an actin-tethered effect on the conformational motion of the integrin, yet the authors' data do not substantiate that conclusion. The authors need to address this in more detail. They can do it in a number of ways, e.g. using cytochalasin D or latrunculin B to destroy the F-actin held to the integrin; blebbistatin to prevent tractional forces from tugging on the integrin; talin or kindlin fragments to uncouple the binding of the integrin to the cytoskeleton.
Other comments: Discussion section is extremely long and reiterative. It should be considerably shortened Referee #3 (Remarks to the Author):
This manuscript addresses the question how the affinity of integrin LFA-1 is regulated during the process of cell adhesion and how allosteric changes within LFA-1 affect ligand (ICAM-1) affinity and impact on cell adhesion. The manuscript is separated in tow parts. First, it analyzes how ICAM-1 affinity changes in respect to conformational modifications of LFA-1 and second, how these affinity changes affect cell adhesion. The experimental approach to measure ICAM-1 affinity by competitive ligand binding assays is very elegant and provides unprecedented insight how different integrin conformational states are coupled to monomeric ICAM-1 binding affinity. Interestingly, subtle increases in ICAM-1 binding affinities induced with reagents such as PMA, SDF-1 or T-cell receptor clustering, contrast with their strong positive effect on cell adhesion. On the other hand, conformational changes that increase ICAM-1 affinity by about 100 fold, such as induced by Mn2+ lead only to a modest increase in cell adhesion. In addition, by inducing different integrin conformational states by specific Fab antibody fragments, the authors measured conformation specific ICAM-1 affinities, covering affinity ranges from 100 to 500 fold. Interestingly, when the authors compared affinity changes to an increase in cell adhesion, they noticed an energy dependent step involved in cell adhesion, which was overcome only in a situation of fully "activated" highaffinity LFA-1 state. Based on their data the authors are proposing an integrin "priming" event resulting in minute changes LFA-1 affinity, which are followed by an energy dependent change to a high-affinity state supporting cell adhesion. Although the manuscript provides answers to important questions in the field, some modification are required to make it more accessible to the reader and clarify certain technical issues that could affect the interpretation of the data.
Model:
For a good understanding of the presented experiments and results, it is important to introduce the experimental system used in this manuscript. However, the current figure is biased towards a model favored by the authors (the current model would be ok for the discussion). It would be more appropriate to introduce the different conformational states of LFA-1, as well as the binding sites of the different antibodies and reagents used in the manuscript. In addition, this figure should also introduce the competitive ligand binding approach, with a description of the TS1/22 binding site to beta5-alpha6 loop and how conformational changes in the alpha-I domain (eventually induced by the different treatments) would affect accessibility, and therefore affinity of ICAM-1 to the MIDAS site. When the authors would like to show introductionary integrin models, it is more appropriate to show both inside-out (conformational regulation by talin and other adapters) as well as outside-in (ligand binding induced conformational changes) regulation. The ability of ICAM-1 to bind to low affinity LFA-1 receptors is a critical prerequisite in order to capture low affinity integrins, dragged along the cell surface by intracellular adapters. Only then, force induced allosteric conformational changes and the associated increase in ICAM-1 affinity can be understood as proposed by the current study.
Competitive ligand binding assay:
After the initial measurement of the affinity of TS1/22 for LFA-1 on IL-15 cultured T lymphocytes (24nM), this experiment is never repeated for different LFA-1 expression systems or for cells, which have been treated with activators such as PMA or SDF-1. Because the authors assume TS1/22 binding is identical in all experimental condition, possible differences caused by changes in the amount of cell surface integrins or other cell surface modifications may cause differences in TS1/22 binding that could influence the affinity measurements for Hi3-ICAM-1. It is therefore important to demonstrate that different cellular conditions used in the different experiments do not affect TS1/22 binding, which could eventually affect the apparent binding constant of ICAM-1.
In addition, the binding of the Hi3-ICAM-1 to LFA-1 in the absence of TS1/22 is measured only once (for the high affinity LFA-1 mutant, affinity in the nM range). However, it would be crucial to measure Hi3-ICAM-1 binding affinity in the absence of TS1/22 at least for non-treated cells, in order to understand how the apparent affinity values for ICAM-1 differ from that measured in the competition assay.
3. Figure 3 A-D. Scale of the vertical axis of the adhesion assay should be the same for all four conditions. In fact, the treatment that induces the strongest increase in LFA-1 affinity (Mn2+, about 100-fold) results in the weakest increase in cell adhesion. This result should be specifically commented, since it emphasizes that during cell adhesion, post-ligand-binding events play a greater role than signal induced affinity changes in the LFA-1 receptor prior to ligand binding. In fact, this result strongly suggests that cell adhesion is principally controlled by post-ligand binding processes that regulate for example integrin clustering, such as talin, or alternatively, energy dependent processes that require integrin stretching (between an extracellular ligand and intracellular adapter protein such as talin) as proposed by the authors.
Definition of the primed state:
Based on the slightly increased ICAM-1 affinity upon activation with reagents such as PMA and SDF-1, the authors propose the existence of a "primed state". Based on the presented results, this is likely to be an over-interpretation of the data. In figure 3E ,F, where an approximately 30% increase in the affinity is measured, the fit curve is shifted downwards compared to untreated cells. Because the entire dataset is shifted, the measured increase in affinity (differences at the highest ICAM-1 concentration) may reflect a systematic error, rather than a significant biological effect. Likewise a similar issue is seen in Fig. 5F . In figure 6 , with the exception of Fig. 6C , it is worth discussing whether the measured changes in ICAM-1 affinity in the absence of cellular energy are biologically relevant, and whether the critical differences in cell adhesion in the absence of energy are due to so far unknown post-ligand binding events. We have strengthened the evidence for the rigor of our assay. We add data showing that TS1/22 Fab has identical affinity for low and high affinity LFA-1. Furthermore, we do two comparisons of the 125 I-Fab competition assay and 125 I-Hi3-ICAM-1 binding assay, on the high affinity state stabilized by Fab, and on the K287C/K294C mutant. The latter provides novel insights and demonstrates the power of the competition assay for detecting subpopulations with different affinities.
2) Does the high-affinity F265S/F292A mutant support adhesion?
Yes. We add a supplementary figure. 3) Additional discussion of why MEM148 is unable to produce a high-affinity state is required.
MEM148 is described as binding to a β2 hybrid domain activation epitope and inducing hybrid domain swing-out. Hence, its inability to generate high affinity LFA-1 does not appear to be consistent with the proposed activation pathway whether priming is correlated with alterations in the integrin leg conformations that then lead to hybrid domain swing out, opening of the β I-domain and ultimately activation of the α subunit I-domain.
It actually is an activation-reporting antibody, so it is easy to understand why it does not induce high affinity. This is now discussed.
4) At several points the authors state that results demonstrate that cell adhesion requires postligand binding events that open the LFA-1 headpiece and induce high affinity. What is the evidence that it is post-ligand binding? This is certainly credible, and it would be consistent with the traction model, but the proof that it is post ligand binding needs to be more clearly explained.
We now add a clear explanation.
5) The reported results are consistent with the traction force model for activation but do not directly reveal any role for traction. This should be clear in the discussion.
We agree, and have made this clear.
Referee #2 (Remarks to the Author):

This study from Schürpf and Springer addresses an important, unresolved topic, which is the regulation of the affinity of the LFA-1/αLβ2 integrin on the surface of T cells. The authors use a high affinity mutant of ICAM-1; integrin mutants; T cell stimuli that modulate cell adhesion, e.g. chemokines and TCR/CD3 activation; conformation-sensitive and conformation-changing Fab antibody fragments; and small molecule inhibitors to study the conformational changes in LFA-1 that lead to intermediate and high affinity conformations, and how these support T cell adhesion. The major conclusions are: 1) Inside-out stimulation of LFA-1-mediated T cell adhesion produces only modest increase to the affinity of LFA-1; 2) The opening of the integrin headpiece is necessary for the acquisition of a high affinity conformation and T cell adhesion; 3) Immobilized, but not soluble ligand triggers a cellular energy-dependent conformational change.
This represents a comprehensive, well conducted study that sheds light into important questions. LFA-1 is arguably the best characterized integrin receptor in terms of its conformational changes during activation. In this work, the authors have opted for a classical biochemical approach to define the conformational changes that underlie adhesion to ICAM-1 mediated by LFA-1.
1) The authors use a galore of different reagents, which makes the study hard to follow for the nonspecialist. This could be improved by adding an additional panel to Figure 1 (G) . This panel should display the binding sites and effects of the antibodies and reagents used throughout the study.
We have revised Fig. 1 to fulfill the role of explaining the galore of reagents and the competition assay.
2) The difference between T lymphocytes and transfected K562 is interesting, and points to an endogenous partial activator missing in the K562 cells. The authors should study the binding of LFA-1 to Hi3-ICAM-1 in an additional, non-lymphoid cell line, to be added to panels 1C and 1D. This would reveal whether the K562 are a special case, or that T cells contain a cellular activator that triggers partial activation of LFA-1.
It was revealed years ago that LFA-1 expressed in different cell types differs markedly in adhesiveness, and references to this are added. However, one more cell type would not be enough to explore this. A third cell could correlate with one or the other. Since we are talking about correlations between cell lineage and affinity phenotype, a large panel of cell types would be required. We believe that this is more appropriate for another paper. Fig. 3D, 
3) A point that needs to be solved is that in
the percentage of adherent cells induced by Mn2+ seems to be rather low (only about 25%), specially taking into account the unusually high concentration of this cation employed to induce activation of LFA-1 (1 uM). Also, why are the % adherent cells so different under the "control" (basal) conditions in panels A, B, C, and D of Fig 3, when they should correspond to the same cells(IL-15 cultured T lymphocytes) and conditions (absence of stimulation)?.
The [Mn 2+ ] of 1 mM is standard for my lab. These panels are indeed separate panels, and are not comparable, as assays and washes were separate. Binding in Mn 2+ was consistently lower than in PMA, however. (Chen et al., 2010) , the authors should show representative classes of conformations by negative staining EM.
4) Similar to their own study on αXβ2
All of the antibodies are to the b 2 subunit. They behave similarly functionally on the α L β 2 and α X β 2 . Repeating the work of Chen et al. would not add much scientifically, and would weigh down the paper, which is already data heavy.
The last conclusion of the study is less convincing. 2-DG and azide are bound to cause sledgehammer effects on the cells and are not very informative of the mechanistic effects at work here. Panels 1E and 1F suggest an actin-tethered effect on the conformational motion of the integrin, yet the authors' data do not substantiate that conclusion. The authors need to address this in more detail. They can do it in a number of ways, e.g. using cytochalasin D or latrunculin B to destroy the F-actin held to the integrin; blebbistatin to prevent tractional forces from tugging on the integrin; talin or kindlin fragments to uncouple the binding of the integrin to the cytoskeleton.
Unfortunately, many proteins bind integrin b tails, the cytoskeleton is complex, and there may not be a single integrin activation mechanism. We have softened discussion on the cytoskeleton and traction.
Other comments: Discussion section is extremely long and reiterative. It should be considerably shortened
We have shortened Discussion at several points, and deleted the second-to-last paragraph. 
Model: For a good understanding of the presented experiments and results, it is important to introduce the experimental system used in this manuscript. However, the current figure is biased towards a model favored by the authors (the current model would be ok for the discussion).
We have revised Fig. 1 We have done all this, as explained for Reviewer 1, comment 1. Figure 3 A-D figure 3E ,F, where an approximately 30% increase in the affinity is measured, the fit curve is shifted downwards compared to untreated cells. Because the entire dataset is shifted, the measured increase in affinity (differences at the highest ICAM-1 concentration) may reflect a systematic error, rather than a significant biological effect. Likewise a similar issue is seen in Fig. 5F . In figure 6 , with the exception of Fig. 6C , it is worth discussing whether the measured changes in ICAM-1 affinity in the absence of cellular energy are biologically relevant, and whether the critical differences in cell adhesion in the absence of energy are due to so far unknown post-ligand binding events.
3.
We have added supplemental Fig. 2 , which shows that fixing maximum binding at 100% has no effect on affinity or significance. Many thanks for submitting the revised version of your manuscript EMBOJ-2011-78276R. It has now been seen again by all three referees, whose comments are enclosed below. As you will see, all the referees find the study well revised and suitable for publication in EMBOJ. Referee 2 does just have a couple of remaining comments. Specifically, he/she requests that the final sentence of the abstract be removed or modified to avoid over-statement. As for his/her second comment -regarding the use of an additional cell line beyond T-cells and K562 cells, I would be inclined to agree with you that this lies beyond the scope of this study, and so you don't need to do anything here.
If you could just modify the abstract accordingly, and email back the text file, we can then upload this into the system. We should then be able to accept the manuscript for publication without further delay.
Many thanks for choosing EMBOJ for publication of this study, and congratulations on a fine piece of work!
